Cancer treatment is one of the hottest areas of healthcare investing these days, with personalized medicine like genetic therapies providing new promises of treatment and potential cures. Still, despite the progress that researchers have made, there are still plenty of false starts and treatments that don't end up delivering on the hopes their inventors and investors had for them.
To cut through the clutter, we asked three Motley Fool contributors to pick a cancer treatment stock that looked worthy of investment. They selected Bristol-Myers Squibb (NYSE: BMY), Intuitive Surgical (NASDAQ: ISRG), and Myriad Genetics (NASDAQ: MYGN). Read on to find out why and to better inform your decision on whether these companies deserve a place in your portfolio.
Image Source: Getty Images